Diagnostische Genauigkeit eines Panels bakterieller Genmarker (M3) für kolorektale fortgeschrittene Neoplasien (M3-PRO)
Eine prospektive Querschnittsstudie zur Bewertung der diagnostischen Genauigkeit eines Panels bakterieller Genmarker (M3) für fortgeschrittene kolorektale Neoplasien
The investigators aim to evaluate and compare the diagnostic accuracy of FIT and the novel panel of bacterial gene markers (Fn, m3, Ch and Bc) collectively named as M3, in detecting colorectal advanced neoplasia.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Colorectal cancer (CRC) is the one of the most common cancers in Hong Kong with more than 5,500 new cases annually. There is prevailing evidence of increasing trend of young onset CRC globally. Early detection and resection of pre-malignant colorectal neoplasia has shown to reduce CRC-related mortality.
Non-invasive stool tests including guaiac-based faecal occult blood tests (gFOBT) and faecal immunochemical tests (FIT) are the cornerstones of population-based CRC screening programmes. The major limitation of this widely used strategy is its unsatisfactory sensitivities for CRC (79%) and advanced adenomas (AA; 40%). The sensitivity for non-advanced adenomas is even lower than 10%. A large proportion of advanced and non-advanced adenomas will be missed by FIT alone. Therefore, identification of alternative non-invasive test with better sensitivity to detect colorectal neoplasia is warranted.
Multitarget stool DNA test and faecal microbial DNA markers appear to be promising options for CRC screening. Several bacterial gene markers have been identified by metagenome sequencing and reported to be associated with CRC, including Fusobacterium nucleatum (Fn), Clostridium hathewayi (Ch) and Bacteroides clarus (Bc). However, these molecular markers had low accuracy in distinguishing adenomas from normal tissue. Recently, a new Lachnoclostridium gene marker (labelled as 'm3') has been shown to have high diagnostic yield for the detection of colorectal adenomas. In a case-control study of 1012 subjects, a linear increasing trend of m3 level was observed from fecal samples of healthy subjects to those with adenomas and cancers. The overall sensitivity of m3 was significantly higher than FIT in detecting all adenomas (48% vs 9.3%), AA (50.8% vs 16.1%) and non-advanced adenomas (44.2% vs 0%). The diagnostic accuracy of m3 could be further enhanced by combining with a panel of fecal microbial markers composing of Fusobacterium nucleatum (Fn), Bacteroides clarus (Bc), Clostridium hathewayi (Ch) for CRC (82.3%) and adenomas (64.2%). We hypothesized that the combination of these 4 bacterial gene markers (known as M3) is more sensitive than FIT in detecting colorectal advanced neoplasia.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
-
Hong Kong, Hongkong
- Prince of Wales Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Subjects with average risk of colorectal neoplsia requring screening/surveillance colonoscopy
Beschreibung
Inclusion Criteria:
- They require elective colonoscopy for colorectal cancer screening or polyp surveillance, or investigation of symptoms (e.g. anemia, change of bowel habit, abdominal pain);
- Aged ≥18 years old;
- Written informed consent obtained.
Exclusion Criteria:
- Contraindications to colonoscopy (e.g. perforation, intestinal obstruction, unstable cardiopulmonary status);
- Contraindication to polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets);
- Known colorectal cancer or adenoma for staged procedure;
- Previous colonic resection;
- Personal history of colorectal cancer;
- Personal history of polyposis syndrome;
- Personal history of inflammatory bowel disease;
- Known pregnancy or lactation;
- Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above);
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: CASE_ONLY
- Zeitperspektiven: CROSS_SECTIONAL
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Colorectal neoplasia screening/surveillance cohort
Subjects with average risk of colorectal neoplasias requiring screening/surveillance colonoscopy |
A kind of stool test
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Sensitivity of bacterial gene markers panel (M3)
Zeitfenster: 1 month
|
The proportion of subjects with true positive results of M3 among those with one of more advanced neoplasia detected in the index colonoscopy. |
1 month
|
|
Sensitivity of FIT/FOBT
Zeitfenster: 1 month
|
The proportion of subjects with true positive results of FIT among those with one of more advanced neoplasia detected in the index colonoscopy. |
1 month
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Sensitivity of M3 for early-stage (stage 1) or invasive (stage 2-4) colorectal cancers
Zeitfenster: 1 month
|
The proportion of subjects with true positive results of M3 among those with early-stage (stage 1) or invasive (stage 2-4) colorectal cancers detected in the index colonoscopy. |
1 month
|
|
Sensitivity of FIT/FOBT for early-stage (stage 1) or invasive (stage 2-4) colorectal cancers
Zeitfenster: 1 month
|
The proportion of subjects with true positive results of FIT among those with early-stage (stage 1) or invasive (stage 2-4) colorectal cancers detected in the index colonoscopy. |
1 month
|
|
Sensitivity of FIT/FOBT for advanced adenomas
Zeitfenster: 1 month
|
The proportion of subjects with true positive results of FIT among those with one or more advanced adenomas detected in the index colonoscopy. |
1 month
|
|
Sensitivity of M3 for advanced adenomas
Zeitfenster: 1 month
|
The proportion of subjects with true positive results of M3 among those with one or more advanced adenomas detected in the index colonoscopy. |
1 month
|
|
Sensitivity of FIT/FOBT for all adenomas
Zeitfenster: 1 month
|
The proportion of subjects with true positive results of FIT among those with all advanced adenomas detected in the index colonoscopy. |
1 month
|
|
Sensitivity of M3 for all adenomas
Zeitfenster: 1 month
|
The proportion of subjects with true positive results of M3 among those with all advanced adenomas detected in the index colonoscopy. |
1 month
|
|
Sensitivity of FIT/FOBT for sessile serrated lesions (SSL)
Zeitfenster: 1 month
|
The proportion of subjects with true positive results of FIT among those with SSLs detected in the index colonoscopy. |
1 month
|
|
Sensitivity of M3 for sessile serrated lesions (SSL)
Zeitfenster: 1 month
|
The proportion of subjects with true positive results of M3 among those with SSLs detected in the index colonoscopy. |
1 month
|
|
Specificity
Zeitfenster: 1 month
|
The proportion of true negative results of M3/FOBT/FIT among those with no adenoma detected in colonoscopy |
1 month
|
|
Positive predictive value (PPV)
Zeitfenster: 1 month
|
The ratio of subjects truly diagnosed as positive to all those who had positive test results |
1 month
|
|
Negative predictive value (NPV)
Zeitfenster: 1 month
|
The ratio of subjects truly diagnosed as negative to all those who had negative test results |
1 month
|
|
Overall diagnostic accuracy
Zeitfenster: 1 month
|
The proportion of correctly classified subjects among all subjects |
1 month
|
|
Microbiota changes in subjects with adenomas or normal findings after polypectomy
Zeitfenster: 1 month
|
Microbiota change measured by qPCR or metagenomic sequencing |
1 month
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2022.170
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .